Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats

European Journal of Pharmacology

Volumn 519, Issue 3, 2005, Pages 267-276

  Grönholm, Tina ^a,b   Zhong, Jian Cheng ^c   Palojoki, Eeva ^a,b   Eriksson, Anders ^a   Bäcklund, Tom ^a,b   Vuolteenaho, Olli ^d   Finckenberg, Piet ^c   Laine, Mika ^a,b   Mervaala, Eero ^c   Tikkanen, Ilkka ^a,b  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF OULU   (Finland)

Author keywords

Angiotensin converting enzyme inhibition; Cardiomyopathy; Diabetes; Hypertension; Vasopeptidase inhibition

Indexed keywords

ENALAPRIL; OMAPATRILAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HIGH SODIUM INTAKE; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOMEGALY; COLLAGEN; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; ENALAPRIL; FIBROSIS; HEART; INSULIN; MALE; METALLOENDOPEPTIDASES; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; ORGAN SIZE; PROTEASE INHIBITORS; PYRIDINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY; THIAZEPINES;

EID: 24644491699     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.07.015     Document Type: Article

References (46)

1. S.G. Ball Benefits of blood pressure reduction in diabetic patients J. Hypertens. 21 2003 S31 S36 (Suppl)
2. T. Bäcklund, E. Palojoki, T. Grönholm, A. Eriksson, O. Vuolteenaho, M. Laine, and I. Tikkanen Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo Pharmacol. Res. 44 2001 411 418
3. T. Bäcklund, E. Palojoki, A. Saraste, T. Grönholm, A. Eriksson, P. Lakkisto, O. Vuolteenaho, M.S. Nieminen, L.-M. Voipio-Pulkki, M. Laine, and I. Tikkanen Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction Cardiovasc. Res. 57 2003 727 737
4. W.W. Brooks, O.H.L. Bing, K.G. Robinson, M.T. Slawsky, D.M. Chaletsky, and C.H. Conrad Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat Circulation 96 1997 4002 4010
5. J.C. Burnett Jr. Vasopeptidase inhibition; a new concept in blood pressure management J. Hypertens. 17 1999 S37 S43
6. L.M. Burrell, J. Droogh, O. Man in't Veld, M.D. Rockell, N.K. Farina, and C.I. Johnston Antihypertensive and antihypertrophic effects of omapatrilat in SHR Am. J. Hypertens. 13 2000 1110 1116
7. D.J. Campbell Vasopeptidase inhibition: a double-edged sword? Hypertension 41 2003 383 389
8. A. Cataliotti, G. Boerrigter, H.H. Chen, M. Jougasaki, L.C. Costello, T. Tsuruda, S.-C. Lee, L.S. Malatino, and J.C. Burnett Jr. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure Circulation 105 2002 639 644
9. Z.J. Cheng, T. Vaskonen, I. Tikkanen, K. Nurminen, H. Ruskoaho, H. Vapaatalo, D. Muller, J.-K. Park, F.C. Luft, and E.M.A. Mervaala Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats Hypertension 37 2001 433 439
10. S. Cosson, and J.P. Kevorkian Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab. 29 2003 455 466
11. F. El-Atat, S.I. McFarlane, and J.R. Sowers Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management Curr. Hypertens. Rep. 6 2004 215 223
12. M.M. El-Omar, Z.-K. Yang, A.O. Phillips, and A.M. Shah Cardiac dysfunction in the Goto-Kakizaki rat Basic Res. Cardiol. 99 2004 133 141
13. P. Finckenberg, K. Inkinen, J. Ahonen, S. Merasto, M. Louhelainen, H. Vapaatalo, D. Muller, D. Ganten, F. Luft, and E. Mervaala Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways Am. J. Pathol. 163 2003 355 366
14. S. Fredersdorf, C. Thumann, C. Ulucan, D.P. Griese, A. Luchner, G.A.J. Riegger, E.P. Kromer, and J. Weil Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats Cardiovasc. Pathol. 13 2004 11 19
15. J. Galli, H. Fakhrai-Rad, A. Kamel, C. Marcus, S. Norgren, and H. Luthman Pathophysiological and genetic characterization of the major diabetes locus in GK rats Diabetes 48 1999 2463 2470
16. Y. Goto, M. Kakizaki, and N. Masaki Production of spontaneous diabetic rats by repetition of selective breeding Tohoku J. Exp. Med. 119 1976 85 90
17. T. Grönholm, P. Finckenberg, E. Palojoki, A. Saraste, T. Bäcklund, A. Eriksson, M. Laine, E. Mervaala, and I. Tikkanen Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet Hypertens. Res. 27 2004 609 618
18. L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, J. Menard, K.H. Rahn, H. Wedel, and S. Westerling Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 351 1998 1755 1762
19. U. Janssen, A.O. Phillips, and J. Floege Rodent models of nephropathy associated with type II diabetes J. Nephrol. 12 1999 159 172
20. U. Janssen, S.G. Riley, A. Vassiliadou, J. Floege, and A.O. Phillips Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy Kidney Int. 63 2003 2162 2170
21. M. Laakso Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention J. Intern. Med. 249 2001 225 235
22. S.E. Litwin, S.E. Katz, J.P. Morgan, and P.S. Douglas Thrombosis/thrombolysis/vasodilator responses: serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat Circulation 89 1994 345 354
23. T. Majalahti-Palviainen, M. Hirvinen, V. Tervonen, M. Ilves, H. Ruskoaho, and O. Vuolteenaho Gene structure of a new cardiac hormone: a model for heart-specific gene expression Endocrinology 141 2000 731 740
24. S.A. Metz, M. Meredith, J. Vadakekalam, M.E. Rabaglia, and A. Kowluru A defect late in stimulus-secretion coupling impairs insulin secretion in Goto-Kakizaki diabetic rats Diabetes 48 1999 1754 1762
25. E. Millette, B. Demeilliers, R. Wu, M.-A. Laplante, A. El Midaoui, P. Moreau, D. Lamontagne, and J. de Champlain Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension J. Hypertens. 21 2003 125 135
26. K. Mizushige, L. Yao, T. Noma, H. Kiyomoto, Y. Yu, N. Hosomi, K. Ohmori, and H. Matsuo Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model Circulation 101 2000 899 907
27. A. Monopoli, A. Forlani, and E. Ongini Chronic inhibition of NEP reduces left ventricular hypertrophy without changing blood pressure in spontaneously hypertensive rats J. Hypertens. 9 1991 S246 S247 (Suppl)
28. H. Mosén, A. Salehi, P. Alm, R. Henningsson, J. Jimenez-Feltström, C.-G. Östenson, S. Efendic, and I. Lundquist Defective glucose-stimulated insulin release in the diabetic Goto-Kakizaki (GK) rat coincides with reduced activity of the islet carbon monoxide signaling pathway Endocrinology 146 2005 1553 1558
29. E. Nunez, K. Hosoya, D. Susic, and E.D. Frohlich Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR Hypertension 29 1997 519 524
30. J.R. Privratsky, L.E. Wold, J.R. Sowers, J.R. Quinn, T. Mark, and J. Ren AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NAPDH oxidase Hypertension 42 2003 206 212
31. T. Quaschning, L.V. d'Uscio, S. Shaw, and T.F. Luscher Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension Hypertension 37 2001 1108 1113
32. S.G. Riley, R. Steadmen, J.D. Williams, J. Floege, and A.O. Phillips Augmentation of kidney injury by basic fibroblast growth factor or platelet-derived growth factor does not induce progressive diabetic nephropathy in the Goto-Kakizaki model of non-insulin-dependent diabetes J. Lab. Clin. Med. 134 1999 304 312
33. L.M. Ruilope, A. Coca, M. Volpe, and B. Waeber Ace inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am. J. Hypertens. 15 2002 367 371
34. B.F. Schrijvers, A.S. De Vriese, J. Van de Voorde, R. Rasch, N.H. Lameire, and A. Flyvbjerg Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes Nephrol. Dial. Transplant. 19 2004 1092 1097
35. T. Tikkanen, I. Tikkanen, M.D. Rockell, T.J. Allen, C.I. Johnston, M.E. Cooper, and L.M. Burrell Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus Hypertension 32 1998 778 785
36. C. Tourrel, D. Bailbe, M. Lacorne, M.-J. Meile, M. Kergoat, and B. Portha Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4 Diabetes 51 2002 1443 1452
37. N.C. Trippodo, J.A. Robl, M.M. Asaad, M. Fox, B.C. Panchal, and T.R. Schaeffer Effects of omapatrilat in low, normal and high renin experimental hypertension and diabetes mellitus Am. J. Hypertens. 11 1998 363 372
38. R.W. Troughton, M.T. Rademaker, J.D. Powell, T.G. Yandle, E.A. Espiner, and C.M. Frampton Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure Hypertension 36 2000 523 530
39. C. Tshöpe, T. Walther, J. Königer, F. Spillmann, D. Westermann, and F. Escher Prevention of cardiac fibrosis and left ventricular dysfunction in rats by transgenic expression of the human tissue kallikrein gene FASEB J. 18 2004 828 835
40. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 712
41. M.I. Uusitupa, J.N. Mustonen, and K.E. Airaksinen Diabetic heart muscle disease Ann. Med. 22 1990 377 386
42. D.L. Vesely, W.R. Gower Jr., J.R. Dietz, R.M. Overton, L.C. Clark, E.K. Antwi, and R.V. Farese Elevated atrial natriuretic peptides and early renal failure in type 2 diabetic Goto-Kakizaki rats Metabolism 48 1999 771 778
43. O. Vuolteenaho, P. Koistinen, V. Martikkala, T. Takala, and J. Leppäluoto Effect of physical exercise in hypobaric conditions on atrial natriuretic peptide secretion Am. J. Physiol. 263 1992 R647 R652
44. K. Witte, K. Jacke, R. Stahrenberg, G. Arlt, I. Reitenbach, L. Schilling, and B. Lemmer Dysfunction of soluble guanylyl cyclase in aorta and kidney of Goto-kakizaki rats: influence of age and diabetic state Nitric Oxide 6 2002 85 95
45. G. Ye, N.S. Metreveli, R.V. Donthi, S. Xia, M. Xu, E. Carlson, and P.N. Epstein Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes Diabetes 53 2004 1336 1343
46. A. Zanchetti, and L.M. Ruilope Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J. Hypertens. 20 2002 2099 2110